Research Papers: Gerotarget (Focus on Aging):
Influence of non-steroidal anti-inflammatory drugs on Drosophila melanogaster longevity
Metrics: PDF 2936 views | HTML 2979 views | ?
Anton Danilov1,2, Mikhail Shaposhnikov2,3, Oksana Shevchenko2, Nadezhda Zemskaya2, Alex Zhavoronkov4 and Alexey Moskalev1,2,3,5
1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
2 Institute of Biology of Komi Science Center of Ural Branch of RAS, Syktyvkar, Russia
3 Syktyvkar State University, Syktyvkar, Russia
4 Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
5 Moscow Institute of Physics and Technology, Dolgoprudny, Russia
Alexey Moskalev, email:
Keywords: longevity, anti-inflammatory drugs, Drosophila, lifespan, geroprotector, geotarget
Received: May 27, 2015 Accepted: July 17, 2015 Published: August 07, 2015
Most age-related diseases and aging itself are associated with chronic inflammation. Thus pharmacological inhibition of inflammatory processes may be effective antiaging strategy. In this study we demonstrated that treatment of Drosophila melanogaster with 10 non-steroidal anti-inflammatory drugs (NSAIDs: CAY10404, aspirin, APHS, SC-560, NS-398, SC-58125, valeroyl salicylate, trans-resveratrol, valdecoxib, licofelone) leads to extension of lifespan, delays age-dependent decline of locomotor activity and increases stress resistance. The effect of the lifespan increase was associated with decrease of fecundity. Depending on the concentration, NSAIDs demonstrated both anti- and pro-oxidant properties in Drosophila tissues. However, we failed to identify clear correlation between antioxidant properties of NSAIDs and their pro-longevity effects. The lifespan extending effects of APHS, SC-58125, valeroyl salicylate, trans-resveratrol, valdecoxib, and licofelone were more pronounced in males, valdecoxib and aspirin - in females. We demonstrated that lifespan extension effect of NSAIDs was abolished in flies with defective genes involved in Pkh2-ypk1-lem3-tat2 pathway.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.